Drug Trial Radar · NCT07680764
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Sep 10, 2026
Primary completion
Sep 15, 2028
Study completion Sep 15, 2030
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jul 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability, and efficacy of Imzokitug in combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as first-line treatment for participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Conditions
- Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
- Metastatic Non-Small Cell Lung Cancer (NSCLC)
Interventions
PumitamigDrug
Specified dose on specified days
ImzokitugDrug
Specified dose on specified days
PemetrexedDrug
Specified dose on specified days
CisplatinDrug
Specified dose on specified days
CarboplatinDrug
Specified dose on specified days
PaclitaxelDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR) by investigator (per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1)Time frame: Up to approximately 4 years
Locations
74 sites in 12 countries. Site status is shown where the registry gives one.
Local Institution - 0183
Washington D.C., District of Columbia · Not yet recruiting
University Cancer & Blood Center, LLC
Athens, Georgia · Recruiting
Baptist Health Lexington
Lexington, Kentucky · Recruiting
Baptist Health Hamburg
Lexington, Kentucky · Recruiting
Local Institution - 0123
Baltimore, Maryland · Not yet recruiting
Hattiesburg Clinic
Hattiesburg, Mississippi · Recruiting
Nebraska Cancer Specialists
Grand Island, Nebraska · Recruiting
Oncology Hematology West PC
Omaha, Nebraska · Recruiting
Local Institution - 0080
New York, New York · Not yet recruiting
Local Institution - 0176
Columbus, Ohio · Not yet recruiting
Local Institution - 0095
Houston, Texas · Not yet recruiting
Local Institution - 0135
Madison, Wisconsin · Not yet recruiting
Instituto Medico Especializado Alexander Fleming
Buenos Aires, Argentina · Recruiting
Clinica Viedma S.A.
Viedma, Argentina · Recruiting
Sanatorio Parque Rosario
Rosario, Santa Fe Province, Argentina · Recruiting
Gosford Hospital
Gosford, New South Wales, Australia · Recruiting
Local Institution - 0134
Westmead, New South Wales, Australia · Not yet recruiting
Local Institution - 0167
Greenslopes, Queensland, Australia · Not yet recruiting
Local Institution - 0100
Heidelberg, Victoria, Australia · Not yet recruiting
St. John of God Murdoch Hospital
Perth, Western Australia, Australia · Recruiting
Local Institution - 0001
São Paulo, Brazil · Not yet recruiting
Local Institution - 0003
Natal/RN, Rio Grande do Norte, Brazil · Not yet recruiting
Local Institution - 0006
Porto Alegre, Rio Grande do Sul, Brazil · Not yet recruiting
Local Institution - 0005
Barretos, São Paulo, Brazil · Not yet recruiting
Orlandi Oncologia
Santiago, Santiago Metropolitan, Chile · Recruiting
Bradfordhill
Santiago, Santiago Metropolitan, Chile · Recruiting
Oncocentro Apys
Viña del Mar, Valparaiso, Chile · Recruiting
Local Institution - 0038
Beijing, Beijing Municipality, China · Not yet recruiting
Local Institution - 0138
Fuzhou, Fujian, China · Not yet recruiting
Local Institution - 0050
Wuhan, Hubei, China · Not yet recruiting
Local Institution - 0147
Nanjing, Jiangsu, China · Not yet recruiting
Local Institution - 0140
Shanghai, Shanghai Municipality, China · Not yet recruiting
Local Institution - 0169
Shanghai, Shanghai Municipality, China · Not yet recruiting
Local Institution - 0144
Chengdu, Sichuan, China · Not yet recruiting
Local Institution - 0137
Hangzhou, Zhejiang, China · Not yet recruiting
Local Institution - 0047
Grenoble, France · Not yet recruiting
Assistance Publique Hôpitaux de Marseille - Hôpital Nord
Marseille, France · Recruiting
Hopitaux Universitaires Paris Centre-Hopital Cochin
Paris, France · Recruiting
Local Institution - 0085
Saint-Herblain, France · Not yet recruiting
Local Institution - 0131
Nice, Alpes-Maritimes, France · Not yet recruiting
Showing 40 of 74 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.